Stockscreener 앱 받기
2.61
11.06%
0.26
시간 외 거래:
2.70
0.09
+3.45%
전일 마감가:
$2.35
열려 있는:
$2.39
하루 거래량:
1.81M
Relative Volume:
1.28
시가총액:
$582.73M
수익:
-
순이익/손실:
$-283.26M
주가수익비율:
-1.381
EPS:
-1.89
순현금흐름:
$-273.61M
1주 성능:
+7.85%
1개월 성능:
-33.08%
6개월 성능:
-68.40%
1년 성능:
-38.59%
1일 변동 폭
$2.37
$2.73
1주일 범위
$2.29
$2.73
52주 변동 폭
$2.29
$12.00
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 400, SEATTLE
SANA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SANA | 2.61 | 582.73M | 0 | -283.26M | -273.61M | -1.89 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology: The Story Becomes Murkier (NASDAQ:SANA) - Seeking Alpha
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology (NASDAQ:SANA) Reaches New 1-Year LowHere's Why - MarketBeat
10 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot - Investing.com India
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio - Quantisnow
Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology stock hits 52-week low at $2.75 By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology stock hits 52-week low at $2.75 - Investing.com India
Sana Biotech sustains stock target with Buy rating on Q3 earnings - Investing.com Nigeria
Analyst keeps Buy on Sana Biotechnology, adjusts outlook as blood cancer competition rises - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year LowWhat's Next? - MarketBeat
Sana Biotechnology Inc Still Hasn’t Convinced Analysts? - Stocks Register
HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA) - MarketBeat
Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities - MSN
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results - TipRanks
Sana: Q3 Earnings Snapshot - The Washington Post
Sana Biotechnology Inc. (SANA) Quarterly 10-Q Report - Quartzy
Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q3 Loss $-0.27 Per Share - Marketscreener.com
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
HC Wainwright Issues Positive Estimate for SANA Earnings - Defense World
HC Wainwright Issues Optimistic Forecast for SANA Earnings - MarketBeat
Sana Biotechnology refocuses on autoimmune and diabetes therapies By Investing.com - Investing.com Australia
Sana lowered to market perform by JMP over data uncertainty - MSN
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low on Analyst Downgrade - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $8.00 at HC Wainwright - MarketBeat
Sana Biotechnology stock hits 52-week low at $3.05 - Investing.com
Sana to lay off staff, deepen autoimmune focus in latest retrenchment - BioPharma Dive
500: Something went wrong - Investing.com UK
Sana Biotechnology stock hits 52-week low at $3.05 By Investing.com - Investing.com Canada
JMP Securities Downgrades Sana Biotechnology (NASDAQ:SANA) to Market Perform - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotech stock target cut, buy rating held on pipeline restructuring - Investing.com UK
Sana Biotechnology refocuses on autoimmune and diabetes therapies - Investing.com
Sana Biotechnology Announces Increased Focus on Type 1 - GlobeNewswire
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.6%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Up 7.7%Still a Buy? - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.4%What's Next? - MarketBeat
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts - Insider Monkey
Biotech stock tumbles after unexplained 1,446% gain - MSN
Sana Biotechnology Inc (SANA) looking to reclaim success with recent performance - SETE News
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mulligan Richard | Director |
Sep 24 '24 |
Sale |
4.08 |
150,000 |
612,570 |
2,848,121 |
| Mulligan Richard | Director |
Sep 25 '24 |
Sale |
3.89 |
150,000 |
583,170 |
2,698,121 |
1.89%
2.08%
자본화:
|
볼륨(24시간):